Provided by Tiger Trade Technology Pte. Ltd.

crane

205.07
-1.6750-0.81%
Pre-market: 206.751.68+0.82%08:45 EDT
Volume:573.96K
Turnover:117.63M
Market Cap:11.81B
PE:35.79
High:206.38
Open:204.43
Low:202.91
Close:206.75
52wk High:230.50
52wk Low:159.58
Shares:57.60M
Float Shares:48.76M
Volume Ratio:1.61
T/O Rate:1.18%
Dividend:0.97
Dividend Rate:0.47%
EPS(TTM):5.73
EPS(LYR):6.26
ROE:16.52%
ROA:12.73%
PB:5.42
PE(LYR):32.78

Loading ...

Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 30

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

GlobeNewswire
·
Mar 30

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

Benzinga
·
Mar 26

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

GlobeNewswire
·
Mar 26

Do Macro Shocks Reveal Hidden Cyclicality In Crane (CR)’s Specialized Technology Story?

Simply Wall St.
·
Mar 25

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

GlobeNewswire
·
Mar 23

Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Dow Jones
·
Mar 20

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

GlobeNewswire
·
Mar 19

Crane Company publishes 2025 annual report, net sales rise 8%

Reuters
·
Mar 13

Crane Company announces annual stockholders meeting

Reuters
·
Mar 13

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

GlobeNewswire
·
Mar 10

Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Mar 09

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

GlobeNewswire
·
Mar 09

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

GlobeNewswire
·
Mar 05